Emerald Health Botanicals a subsidiary of Emerald Health Therapeutics (TSXV:EMH; OTCQX:TBQBF) established an advisory board for strategic guidance regarding its continuing product and market development.
As quoted in the press release:
The Advisory Board includes researchers and physicians specializing in pain management, addiction research, immunology, natural medicines, and pharmaceutical product development, as well experts in cannabinoids and the endocannabinoid system.
“We are honoured to have these established individuals form our Advisory Board and guide our company as we push forward with our business plan which includes clinical research to study the effects of our products on client health. Ultimately, we expect to develop pharmaceutical formulations to provide patients with high-quality pharmaceutical-based cannabis products,” says Dr. Avtar Dhillon, Executive Chairman of Emerald. “We view pharmaceutical formulations as the next evolution in the medicinal cannabis market and expect that when and if these types of products become broadly available they will lead to an increase in the number of physicians willing to prescribe cannabis through targeted indications, precise dosages, and more convenient consumption methods. We believe that these products will represent an avenue to building valuable intellectual property in Canada, which could lead to accelerated sales growth and profit margins, while potentially providing future sales opportunities in other emerging medical markets.”